Cord Blood News Volume 7.24 | Jun 25 2015

Postinfarction Functional Recovery Driven by a Three-Dimensional Engineered Fibrin Patch Composed of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells
The authors examined the ability of a three-dimensional engineered fibrin patch filled with human umbilical cord blood-derived mesenchymal stem cells to induce recovery of cardiac function after myocardial infarction. [Stem Cells Transl Med] Abstract

Safety and Efficacy of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells Therapy for Retinal Degeneration
Scientists investigated the safety and efficacy of subretinal injection of human Wharton’s Jelly-derived mesenchymal stem cells on retinal structure and function in Royal College of Surgeons rats. [PLoS One] Full Article

Preserved In Vivo Reconstitution Ability of PBSCs Cryopreserved for a Decade at -80°C
The authors evaluated viability and functions of PBSCs cryopreserved for more than 10 years. Although recovery rate and viability of CD34⁺ cells were significantly decreased, myeloid differentiation potential and in vivo reconstitution and self-renewal potential of CD34⁺ cells in a xenogeneic engraftment assay were maintained for more than 10 years. [Bone Marrow Transplant] Abstract

Epigenetic and Molecular Signatures of Cord Blood CD34⁺ Cells Treated with Histone Deacetylase Inhibitors
The class I and II histone deacetylase inhibitors (HDACIs), valproic acid and scriptaid, were utilized to expand cord blood (CB) CD34⁺ cells ex vivo. Treatment with individual HDACIs demonstrated significantly unique epigenetic and molecular signatures of CB-hematopoietic stem and progenitor cells. [Vox Sang] Abstract

Effect of Chondrocyte-Derived Early Extracellular Matrix on Chondrogenesis of Placenta-Derived Mesenchymal Stem Cells
Researchers evaluated the effect of decellularized chondrocyte-derived extracellular matrix on the chondrogenesis of human placenta-derived mesenchymal stem cells in a pellet culture system. [Biomed Mater] Full Article

Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Overcomes Poor Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC)
Transplant outcomes of patients with AML-MRC have not been reported compared to patients with AML not otherwise specified (AML-NOS). Researchers analyzed transplant outcomes among 147 patients with AML-MRC or AML-NOS who underwent allo-HSCT in a single institution. [Leuk Lymphoma] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Celator^® Pharmaceuticals Announces Positive Induction Response Results from Phase III Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
Celator Pharmaceuticals, Inc. announced final induction response rate results in the Phase III study comparing CPX-351 liposome injection to the standard of care regimen in patients with untreated high-risk (secondary) acute myeloid leukemia. [Celator Pharmaceuticals, Inc.] Press Release

Ontario Invests in Better Health and Economic Opportunity through Support for Ontario Institute for Regenerative Medicine
A new $25 million commitment positions Ontario to be an early adopter of new treatments and technologies emerging from research and commercial developments in regenerative medicine. [Ontario Institute for Regenerative Medicine] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells. Watch the video.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

NEW PhD Position – Drug Releasing, Nanostructured Biomaterials for Adult Stem Cells (Karlsruhe Institute of Technology)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Postdoctoral Research Scientist – Hematopoietic Stem Cell Self-Renewal and Differentiation (University of Oxford)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Harvard Medical School)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Postdoctoral Scientist – Hematopoietic Stem Cell Transplantation (Indiana University)

Postdoctoral Position – Epigenetic Regulation of Hematopoiesis and Leukemia (Karolinska Institutet)

Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.